anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a viscoelastic solution formed by double-head double-tail type surfactant and lubricating and fracturing applications thereof. The novel surfactant containing double heads and double tails is obtained through a series of synthesis steps. The surfactant has a Krafft point of less than 1 ℃. Self-assembling in water to form worm micelle and rare annular micelle with diameter as small as 30nm, and dissolving the surfactant in water to form high-efficiency viscoelasticity solution with excellent lubricating performance. In addition, when the concentration of the surfactant is only 5mmol/L, the solution viscosity can be increased by about 600 times by adding a small amount of inorganic salt, which greatly reduces the use cost. The viscoelastic solution can be used as a water-based lubricant with good performance and also can be used as an oilfield fracturing fluid, and has remarkable application potential.
OBJECTIVES: Functional constipation (FC), a common functional gastrointestinal disorder, is usually overlapping with upper gastrointestinal symptoms (UGS). We aimed to explore the clinical characteristics of patients with FC overlapping UGS along with the related risk factors.
METHODS: The differences in the severity of constipation symptoms, psychological state, quality of life (QoL), anorectal motility and perception function, autonomic function, and the effect of biofeedback therapy (BFT) among patients with FC in different groups were analyzed, along with the risk factors of overlapping UGS.
RESULTS: Compared with patients with FC alone, those with FC overlapping UGS had higher scores in the Patient Assessment of Constipation Symptoms and Self-Rating Anxiety Scale and lower scores in the Short Form-36 health survey (P < 0.05). Patients with FC overlapping UGS also had lower rectal propulsion, more negative autonomic nervous function, and worse BFT efficacy (P < 0.05). Overlapping UGS, especially overlapping functional dyspepsia, considerably affected the severity of FC. Logistic regression model showed that age, body mass index (BMI), anxiety, exercise, and sleep quality were independent factors influencing overlapping UGS in patients with FC.
CONCLUSIONS: Overlapping UGS reduces the physical and mental health and the QoL of patients with FC. It also increases the difficulty in the treatment of FC. Patient's age, BMI, anxiety, physical exercise, and sleep quality might be predictors for FC overlapping UGS.
BACKGROUND: Metabolic bariatric surgery (MBS) advocates multimodal analgesia, discouraging opioid use to minimize side effects, such as nausea and vomiting, during postoperative pain management for quicker recovery. Combining erector spinae plane block (ESPB) with multimodal analgesia aims to reduce opioid consumption, improving postoperative recovery. This study aimed to compare morphine consumption between patients with severe obesity undergoing laparoscopic MBS with and without ESPB.
METHODS: This study enrolled 91 patients with severe obesity who underwent laparoscopic MBS involving either sleeve gastrectomy or Roux-en-Y gastric bypass. Of these, 63 patients were included in this study. The participants were randomly allocated to either the intervention group, which received an ESPB before the standard anesthesia protocol, or the control group, which did not receive pre-anesthesia block. The primary outcome measured was 24-h morphine consumption via a patient-controlled analgesia machine. Secondary outcomes included patients' satisfaction, postoperative numerical rating score, changes over time, and quality of recovery (QoR) using the Thai QoR-35 score.
RESULTS: We found no statistically significant difference in morphine consumption between the intervention group and the control group. Furthermore, our analysis revealed no significant between-group differences in patient satisfaction, postoperative numeric rating score, or QoR across all five aspects evaluated using the Thai QoR-35 score.
CONCLUSIONS: ESPB did not reduce morphine consumption or QoR following laparoscopic MBS. Further studies are required to confirm and identify the reasons for the ineffectiveness of ESPB.
A derivatised microfibrillar cellulose is derivatised to comprise substituents that provide electrostatic and/or steric functionality.  The electrostatic functionality is provided by an anionic charge. The derivatised microfibrillar cellulose forms a gel in water at least one point in the concentration range of from 0.05 to 0.99wt%.  The anionic change can be provided by carboxyl, sulphate, sulphonate, phosphonate or phosphate.  The electrostatic functionality can be provided by both an anionic and cationic charge.  The cellulose can be used in pharmaceutical, cosmetic, fertilizing or pesticidal compositions or products such as a wound dressing or in paper products.
The present invention relates to a zirconia full-ceramic dental repairing material and a preparation method thereof, which belongs to the fields of ceramic materials and the preparation thereof. The zirconia full-ceramic dental repairing material is prepared from 86 to 92 wt% of stable tetragonal-phase zirconia with 3.0 to 5.15 wt% of yttrium oxide, 5 to 10 wt% of fluxing agent and 3 to 4 wt% of agglomerant. The fluxing agent is one or more of substances such as boron-aluminum-silicon system glass, hydroxyapatite and beta-wollastonite. The agglomerant is one or more of substances such as polyvinyl alcohol, carboxymethyl cellulose and a polyacrylic acid. In the preparation method, the zirconia full-ceramic dental repairing material is prepared by mixture, granulation, cold isostatic compaction, plastic removal and agglomeration. Compared with the prior art, the zirconia full-ceramic dental repairing material has the advantages of low preparation process cost, high finished size precision, good repetitiveness, stable quality and superior mechanical synthesis property.
The IMscin002 study (NCT03735121) was a randomized, multi-center, open-label cross-over trial conducted in 179 patients with either PD-L1-positive early-stage NSCLC receiving adjuvant treatment or were chemotherapy-naïve with high PD-L1 stage IV NSCLC. Patients were randomized (1:1) to receive 3 cycles of TECENTRIQ HYBREZA followed by 3 cycles of intravenous atezolizumab (Arm A) or 3 cycles of intravenous atezolizumab followed by 3 cycles of TECENTRIQ HYBREZA (Arm B).

Of the 126 eligible patients, 123 (98%) completed the patient preference questionnaire at the beginning of cycle 6 or after at least two consecutive cycles of each treatment method was administered in case of treatment discontinuation prior to cycle 6. Eighty-seven of 123 patients (71%) reported preferring subcutaneous administration of TECENTRIQ HYBREZA over intravenous atezolizumab and the most common reason was that administration required less time in the clinic; 26 out of 123 patients (21%) reported preferring intravenous atezolizumab over TECENTRIQ HYBREZA and the most common reason was that it felt more comfortable during administration; and 10 out of 123 patients (8%) had no preference for the route of administration.

Patients in both arms could continue to receive treatment after the crossover period for up to 16 cycles (patients with early-stage NSCLC) or until disease progression or unacceptable toxicity (patients with stage IV NSCLC). Of the 107 patients who reached the treatment continuation period, 85 (79%) patients (42 from IV/SC and 43 from SC/IV) chose to continue treatment with the SC route of administration.
ETHNOPHARMACOLOGICAL RELEVANCE: Licorice is widely used clinically as one of the most famous traditional Chinese herbs. Its herb roasted with honey is called honey-processed licorice (HPL). Modern studies have shown that HPL has a stronger cardioprotective ability compared to raw licorice (RL), however the material basis and mechanism of action of the potential cardioprotection have not been fully elucidated.
AIM OF THE STUDY: To screen and validate the material basis of cardioprotection exerted by HPL and to preliminarily predict the potential mechanism of action.
MATERIALS AND METHODS: UPLC-QTOF-MS/MS was used to analyze HPL samples with different processing levels, and differential compounds were screened out through principal component analysis. Network pharmacology and molecular docking were applied to explore the association between differential compounds and doxorubicin cardiomyopathy and their mechanisms of action were predicted. An in vitro model was established to verify the cardioprotective effects of differential compounds.
RESULTS: Six differential compounds were screened as key components of HPL for potential cardioprotection. Based on network pharmacology, 113 potential important targets for the treatment of Dox-induced cardiotoxicity were screened. KEGG enrichment analysis predicted that the PI3K-Akt pathway was closely related to the mechanism of action of active ingredients. Molecular docking results showed that the six differential compounds all had good binding activity with Nrf2 protein. In addition, in vitro experiments had shown that five of the active ingredients (liquiritin, isoliquiritin, liquiritigenin, isoliquiritigenin, and licochalcone A) can significantly increase Dox-induced H9c2 cell viability, SOD activity, and mitochondrial membrane potential, significantly reduces MDA levels and inhibits ROS generation.
CONCLUSION: Liquiritin, isoliquiritin, liquiritigenin, isoliquiritigenin and licochalcone A are key components of HPL with potential cardioprotective capabilities. Five active ingredients can alleviate Dox-induced cardiotoxicity by inhibiting oxidative stress and mitochondrial damage.
The invention relates to a medicinal composition comprising a triazine derivative of the following general formula  I! ##STR1## or a solvate thereof, or a salt thereof, as an active ingredient. In the above formula, R 1  and R 2  may be the same or different and each represents hydrogen, unsubstituted or substituted alkyl aralkyl, or alkenyl, or jointly represent cyclic amino (NR 1  R 2 ) in combination with the adjacent nitrogen atom. The cyclic amino may contain nitrogen, oxygen, or sulfur as a ring member in addition to the adjacent nitrogen and may be further substituted. Excluded is the case in which NR 1  R 2  is NH 2 . The compound of the invention is useful as a therapeutic drug for hepatitis.
The present invention relates to a composition for control of aging and/or extension of life. The composition contains dapsone as the active ingredient which displays excellent results in application. When dapsone (DDS) was introduced, the life of caenorhabditis elegans was extended independent of DAF-16, by slowing down the aging process and reducing activation of mitochondrial complex V protein and cellular dual oxidase 1 (DUOX1). In addition, low rate of oxygen consumption and reduction of ROS formation were confirmed in caenorhabditis elegans. Moreover, ROS generation by paraquat, an oxidative stress inducer, was reduced, and sensitivity to paraquat was noted when dapsone was introduced. Furthermore, structural prediction, molecular and biochemical analyses suggested that the dapsone mechanism of action is through piruvate kinase. In addition, dapsone reduced intracellular expression of NOX and restored degraded mitochondria function in human fibroblasts. Such comprehensive results show that dapsone exhibits excellent life-extending effects at both the macro and cellular levels.
Dental floss brushes, as described herein, are extremely difficult to coat with wax coatings. When conventional waxes are utilized, the floss brush becomes matted and gummy. We have developed an improved wax coating solution which results in a thin, uniform coating with good adhesion characteristics. This invention relates to an improved floss brash product and to a novel process for its manufacture. In particular this invention is directed to an improved floss brash made of a textured, high tenacity nylon yarn which provides the scraping functions of a floss under high tension and the brushing functions of a yarn under low tension. The present yarns require a wax coating to improve lubricity during use. The present product exhibits a uniform, thin wax coating. The present process imparts a thin coating by utilizing a "viscosity lowering agent" in the wax coating solution.
The present invention relates to a purple common perilla capsule and a preparation method thereof, which provides a pure Chinese medicine for treating chronic bronchitis and the preparation method thereof. The Chinese medicinal preparation is prepared from more than ten Chinese herbal medicines such as purple common perilla, white nut, cassia bark, etc. The preparation method of the purple common perilla capsule is divided into four steps: three medicinal materials are made into powder, seven medicinal materials are decocted to obtain a thick paste, and the powder and the thick paste are mixed to make granules, and the granules are filled into capsules. The purple common perilla capsule has a scientific and novel formula, reasonable synergy, complementary medicine effect, simple production process, low cost and convenience for oral taking. The purple common perilla capsule can cure chronic bronchitis, and has obvious therapeutic effect on the symptoms of asthma, tussis, profuse sputum, oppression in chest, palpitation, edema, intolerance of cold, etc. which are caused by pneumonectasis, cor pulmonale, pneumonitis, etc.
PROBLEM TO BE SOLVED: To obtain a liquid enteral nutrition composition having a preventing and treating effect on life ctyle-related diseases, such as ameliorating activities on serum lipid, antiobestic effect, etc., even by tube feeding nutrition for a long period of time, and to provide a method for stabilizing an emulsion of soybean protein. SOLUTION: This liquid enteral nutrition composition comprises >=40 wt.% based on total protein of soybean protein. Especially the liquid enteral nutrition composition contains a necessary and sufficient amount of essential trace elements such as zinc, copper, manganese, selenium, chromium, molybdenum, etc., soybean oligosaccharide, etc., being useful components in soybean by using a soybean milk as a soybean protein source. This method for stabilizing an emulsion of soybean protein comprises adding >=5 mass pts. of a phosphate or a citrate to 100 mass pts. of soybean protein.
The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI.
The present invention relates to a novel Lactococcus lactis subsp. Hordniae UAB10 strain derived from aloe and use thereof. Specifically, it is confirmed that Lactococcus lactis subsp. Hordniae UAB10 of the present invention is not cytotoxic, has excellent IL-6/STAT3 inhibitory activity, does not have antibiotic resistance, does not show hemolytic activity, has an excellent antibacterial effect, and has excellent acid resistance, bile resistance, and intestinal adhesion. Accordingly, the Lactococcus lactis subsp. Hordniae UAB10 strain of the present invention can be usefully used as an active ingredient in a safe anti-inflammatory or antibiotic composition with excellent anti-inflammatory, antibacterial, acid resistance, bile resistance, and intestinal adhesion properties.
Chronic Kidney Disease (CKD) provokes biochemical and systemic alterations, causing bone fragility with an increase in bone fracture risk, extraskeletal calcifications, increased morbidity, and cardiovascular mortality. The complex pathophysiological mechanism causes a syndrome called CKD-MBD (Chronic Kidney Disease - Mineral and Bone Disorders), which includes mineral and bone alterations leading to renal osteodystrophy (ROD). An early diagnosis is therefore essential to prevent the onset of more severe complications. A precise diagnosis of bone disorders and the subsequent administration of the best therapy is difficult without performing a bone biopsy. However, lately, the diagnostic focus is shifting to a series of molecules, the bone turnover markers (BTM), generated by the same bone tissue during the remodeling process, which is proving to be a useful diagnostic tool in the definition of ROD. BTMs are divided into bone formation molecules (amino-terminal propeptide of type 1 procollagen, P1NP; osteocalcin, OC; bone alkaline phosphatase, bALP) and bone resorption molecules (carboxy-terminal cross-linked telopeptide of type 1 collagen, CTX; isoform 5b tartrate-resistant acid phosphatase, TRAP-5b). There are also biomarkers of bone metabolism such as parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and sclerostin. Although PTH is one of the most used molecules, P1NP, bALP, CTX, and TRAP-5b have proven to be superior in the discrimination of low turnover pathologies. The diagnostic capability of these molecules and their potential still require further studies, but clinicians must include BTMs in the diagnostic process of CKD-MBD.
Patients who are randomized to the alternative model of care to guide treatment will not have advanced imaging done and will be referred directly to physical therapy care . If the patient is able to functional progress through phase I and II of physical therapy within 3 weeks and phase III within 5 weeks then they return to sport. If patient are unable to progress the are put on rest as a presumed vertebral injury (spondylolysis).
Cognitive-behavioral therapy (CBT) is effective in reducing the level of anger, hostility and depression present in coronary artery disease (CAD) patients.In Taiwan, Weng et al. also confirmed the eight-week group CBT program not only diminished the emotion disturbances including anger, hostility and depression of CAD, but also significantly prolonged the coagulation time, thus reducing the rate of thrombosis formation. Even though the therapeutic effect of the CBT program was valid, this program is still not accessible for some patients in need because they are not aware of it, or they are restricted by time and transportation. Internet-based therapeutic intervention can overcome the obstacles to access this program at any time and in any place. Presently, structured CBT intervention is provided through the Internet and used widely by patients with physical or psychological problems such as smoking, obesity, or headaches, but not by CAD patients. Therefore, the purpose of this research is to evaluate the effects to reduce the psychological risk factors of a web-based group CBT program in CAD patients. Follow-up assessments will be performed after 3 and 6-month durations. The investigators expect that, after an eight-week group intervention, there will be significant decrease of the psychological risk factors. Moreover, the therapeutic effects can be maintained during the three- and six-month follow-up.evaluate In addition, web-based cognitive -behavioral group therapy will significantly reduce indirect medical costs (travel time and money).
Participants will receive Treatment F on Day 1 of Period 1 and then Treatment G on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
The process of hot casting of flat makeup product, comprises placing a deformable flat mold on a support, pouring hot molten makeup product (70) in the deformable flat mold, solidifying the makeup product poured in the deformable flat mold to cool the product, and demolding the flat solidified make-up product by deformation of the flat deformable mold. A portion of the bottom of the mold is not horizontal when placed on the support. Different products with different colors are successively poured into the deformable flat mold. A cup with openings is positioned on the flat deformable mold. The process of hot casting of flat makeup product, comprises placing a deformable flat mold on a support, pouring hot molten makeup product (70) in the deformable flat mold, solidifying the makeup product poured in the deformable flat mold to cool the product, and demolding the flat solidified make-up product by deformation of the flat deformable mold. A portion of the bottom of the mold is not horizontal when placed on the support. Different products with different colors are successively poured into the deformable flat mold. A cup with openings is positioned on the flat deformable mold, and where the step of pouring is carried out by the opening of the cup. The openings are arranged in the bottom of the cup, and to straight of an imprint (41, 42) corresponding to the deformable flat mold, when the cup is positioned on the mold. Independent claims are included for: (1) a device for hot casting of flat makeup product; (2) a hot molded makeup product; and (3) a flat makeup article.
A novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), a broad-specificity sensing receptor that is a novel branch of the nuclear receptor superfamily, has been discovered. SXR forms a heterodimer with RXR that can bind to and induce transcription from response elements present in steroid-inducible cytochrome P450 genes in response to hundreds of natural and synthetic compounds with biological activity, including therapeutic steroids as well as dietary steroids and lipids. Instead of hundreds of receptors, one for each inducing compound, the invention SXR receptors monitor aggregate levels of inducers to trigger production of metabolizing enzymes in a coordinated metabolic pathway. Agonists and antagonists of SXR are administered to subjects to achieve a variety of therapeutic goals dependent upon modulating metabolism of one or more endogenous steroids or xenobiotics to establish homeostasis. An assay is provided for identifying steroid drugs that are likely to cause drug interaction if administered to a subject in therapeutic amounts. Transgenic animals are also provided which express human SXR, thereby serving as useful models for human response to various agents which potentially impact P450-dependent metabolic processes.